Rare Cancer News & Clinical Trials » Trial

Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

Posted: November 8th, 2019, 3:00pm GMT

Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsor: Antoinette J Wozniak
Not yet recruiting

Study of PF‑06940434 in Patients With Advanced or Metastatic Solid Tumors.

Posted: November 5th, 2019, 3:00pm GMT

Conditions: Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Lung Squamous Cell Carcinoma; Pancreatic Cancer; Bile Duct Cancer; Endometrial Cancer; Melanoma Cancer; Urothelial Cancer
Interventions: Drug: PF-06940434; Drug: PF-06801591
Sponsor: Pfizer
Not yet recruiting

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Posted: November 4th, 2019, 3:00pm GMT

Conditions: Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Cholangiocarcinoma; Sarcoma; Endometrial Cancer
Intervention: Drug: CPL304110
Sponsors: Celon Pharma SA; National Center for Research and Development, Poland
Recruiting

A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)

Posted: October 30th, 2019, 2:00pm GMT

Conditions: Hepatocellular Carcinoma; Liver Cancer; Cholangiocarcinoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Not yet recruiting

Permalink for 'A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers'

A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers

Posted: October 24th, 2019, 2:00pm GMT

Conditions: Gastrointestinal Neoplasms; Cholangiocarcinoma; Pancreatic Neoplasms
Intervention: Drug: BI 905711
Sponsor: Boehringer Ingelheim
Not yet recruiting

Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)

Posted: October 21st, 2019, 2:00pm GMT

Condition: Primary Sclerosing Cholangitis
Interventions: Drug: Simvastatin 40mg; Drug: Placebo oral tablet
Sponsor: Annika Bergquist
Not yet recruiting

Quebec Pancreas Cancer Study

Posted: September 26th, 2019, 2:00pm GMT

Conditions: Pancreas Cancer; Pancreatic Cancer; Pancreas Neoplasm; Pancreas Cyst; Pancreatic Precancerous Condition; Familial Pancreatic Cancer; Hereditary Cancer; Bile Duct Cancer; Ampullary Cancer; Duodenal Cancer; Gallbladder Cancer
Intervention:
Sponsor: George Zogopoulos
Recruiting

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

Posted: September 23rd, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Drug: Fimaporfin and Gemcitabine; Drug: Gemcitabine/Cisplatin chemotherapy
Sponsor: PCI Biotech AS
Recruiting

Futibatinib Vs Gem-Cis Chemo as 1st-Line Treatment of Patients With Advanced CCA Harboring FGFR2 Gene Rearrangements

Posted: September 18th, 2019, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements
Interventions: Drug: TAS-120; Drug: Cisplatin/Gemcitabine
Sponsor: Taiho Oncology, Inc.
Not yet recruiting

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Posted: September 12th, 2019, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Available

Permalink for 'Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma'

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Posted: September 12th, 2019, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR1 Gene Alteration Positive; FGFR2 Gene Alteration Positive; FGFR3 Gene Alteration Positive; IDH1 Gene Mutation; IDH1 NP_005887.2:p.R132C; IDH1 NP_005887.2:p.R132G; IDH1 NP_005887.2:p.R132H; IDH1 NP_005887.2:p.R132L; IDH1 NP_005887.2:p.R132S; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Drug: Ivosidenib; Drug: Pemigatinib
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Not yet recruiting

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Posted: September 5th, 2019, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Procedure: Extend LymphAdenectomy
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Not yet recruiting

Permalink for 'Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma'

Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

Posted: September 4th, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma, Intrahepatic
Intervention: Drug: combined therapy using nab-paclitaxel and gemcitabine chemotherapy
Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting

Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

Posted: September 4th, 2019, 2:00pm GMT

Conditions: Gastrointestinal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Gastric Cancer; Esophageal Cancer; Cholangiocarcinoma; Hepatocellular Carcinoma; Neuroendocrine Tumors; GIST, Malignant
Interventions: Behavioral: Serious Illness Conversation Guide (SICG); Behavioral: Quality of Life (QOL) survey
Sponsor: Stanford University
Recruiting

Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma

Posted: September 2nd, 2019, 2:00pm GMT

Conditions: Cholangiocarcinoma; Bile Duct Cancer
Intervention: Drug: Trifluridine/Tipiracil
Sponsors: Sunnybrook Health Sciences Centre; Taiho Pharma Canada, Inc.
Recruiting

$Permalink for 'Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer'$

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Posted: August 28th, 2019, 2:00pm GMT

Conditions: Advanced Bile Duct Carcinoma; Advanced Gallbladder Carcinoma; Refractory Bile Duct Carcinoma; Refractory Gallbladder Carcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8
Interventions: Drug: Irinotecan; Drug: Irinotecan Hydrochloride; Drug: Trifluridine and Tipiracil Hydrochloride
Sponsors: Mayo Clinic; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting

Permalink for 'Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies'

Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Posted: August 26th, 2019, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; Advanced Gallbladder Carcinoma; Advanced Malignant Solid Neoplasm; Metastatic Cholangiocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Gallbladder Carcinoma; Refractory Malignant Solid Neoplasm; Stage III Gallbladder Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Hilar Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Hilar Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIC Hilar Cholangiocarcinoma AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVA Hilar Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Stage IVB Hilar Cholangiocarcinoma AJCC v8
Interventions: Drug: Avelumab; Radiation: Hypofractionated Radiation Therapy; Drug: Nedisertib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting

Gemcitabine Plus Cisplatin With or Without M7824 in Participants With 1L Biliary Tract Cancer (BTC)

Posted: August 23rd, 2019, 2:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Interventions: Drug: M7824; Drug: Placebo; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting

Participation in Surgical Cancer Care

Posted: August 20th, 2019, 2:00pm GMT

Condition: Cancer
Intervention: Other: Participation with enhanced patient perioperative information
Sponsor: Linkoeping University
Recruiting

Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors

Posted: August 19th, 2019, 2:00pm GMT

Condition: Advanced Hepatobiliary and Malignant Tumors
Intervention: Drug: albumin-bound paclitaxel + oxaliplatin
Sponsor: Dong Wang
Not yet recruiting

Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

Posted: August 16th, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Combination Product: Combination of Lonsurf® and Campto®
Sponsors: RWTH Aachen University; Servier
Not yet recruiting

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Posted: August 2nd, 2019, 2:00pm GMT

Conditions: ARID1A Gene Mutation; ATM Gene Mutation; ATR Gene Mutation; Bile Duct Adenocarcinoma; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK2 Gene Mutation; EMSY Gene Mutation; Fanconi Anemia Complementation Group Gene Mutation; Metastatic Bile Duct Carcinoma; MRE11 Gene Mutation; NBN Gene Mutation; PALB2 Gene Mutation; PTEN Gene Deletion; RAD51 Gene Mutation
Intervention: Drug: Olaparib
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Not yet recruiting

Efficacy of Fistulotomy for Biliary Cannulation

Posted: July 30th, 2019, 2:00pm GMT

Conditions: Cholangiocarcinoma; Choledocholithiasis; Cholangitis; Pancreatic Cancer; Pancreatitis
Interventions: Procedure: Fistulotomy - High experienced.; Procedure: Fistulotomy - Low experienced.; Procedure: Conventional (guidewire) cannulation- High experienced; Procedure: Conventional (guidewire) cannulation - Low experienced
Sponsor: Coordinación de Investigación en Salud, Mexico
Recruiting

Permalink for 'Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors'

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Posted: July 26th, 2019, 2:00pm GMT

Conditions: Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, Pancreatic
Interventions: Drug: LMB-100; Drug: Tofacitinib; Device: Mesothelin Expression
Sponsor: National Cancer Institute (NCI)
Recruiting

The Master Registry of Oncology Outcomes Associated With Testing and Treatment

Posted: July 22nd, 2019, 2:00pm GMT

Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Testing: Genome; Diagnostic Test: Testing: Transcriptome; Diagnostic Test: Testing: Proteome; Drug: Treatment: CAR-T
Sponsor: Taproot Health
Not yet recruiting

A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain

Posted: July 10th, 2019, 2:00pm GMT

Conditions: Liver Cancer; Pancreas Cancer; Stomach Cancer; Bile Duct Cancer
Intervention: Device: Endovascular Denervation
Sponsor: Shanghai Golden Leaf MedTec Co. Ltd
Not yet recruiting

Permalink for 'Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)'

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Posted: July 1st, 2019, 2:00pm GMT

Condition: Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsor: Merck Sharp & Dohme Corp.
Recruiting

$Permalink for 'A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies'$

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Posted: June 27th, 2019, 2:00pm GMT

Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Posted: June 24th, 2019, 2:00pm GMT

Condition: Advanced Cholangiocarcinoma
Interventions: Drug: Anlotinib; Drug: TQB2450
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recruiting

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Posted: June 19th, 2019, 2:00pm GMT

Conditions: Glioma; Cholangiocarcinoma; Solid Tumor; IDH Mutation
Interventions: Drug: Olaparib; Drug: Durvalumab
Sponsor: University Health Network, Toronto
Not yet recruiting

CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization

Posted: June 19th, 2019, 2:00pm GMT

Condition: Liver and Intrahepatic Bile Duct Carcinoma
Interventions: Radiation: Computed Tomography Perfusion Imaging; Procedure: Liver Biopsy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting

Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma

Posted: June 11th, 2019, 2:00pm GMT

Condition: Advanced Cholangiocarcinoma
Interventions: Drug: Toripalimab; Drug: Gemcitabine; Drug: 5- fluorine pyrimidine
Sponsor: Jiangmen Central Hospital
Recruiting

Permalink for 'Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma'

Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Posted: May 15th, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma, Intrahepatic
Intervention: Drug: combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
Sponsor: Shanghai Zhongshan Hospital
Recruiting

Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer

Posted: May 9th, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: nab-paclitaxel
Sponsor: Istituto Clinico Humanitas
Recruiting

Permalink for 'Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer'

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Posted: May 8th, 2019, 2:00pm GMT

Conditions: Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Radiation: External Beam Radiation Therapy; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting

Treatment of Advanced Intrahepatic Cholangiocarcinoma

Posted: May 7th, 2019, 2:00pm GMT

Condition: ICC
Interventions: Drug: Levamisole Hydrochloride; Drug: Anlotinib Hydrochloride Capsules
Sponsors: The First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Xinjiang Medical University; Luoyang Central Hospital; Nanyang Central Hospital; Anyang Tumor Hospital; Third People's Hospital of Jiaozuo; Sanmenxia Central Hospital; pinmei Group General Hospital
Recruiting

Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer

Posted: May 6th, 2019, 2:00pm GMT

Condition: Biliary Tract Cancer
Interventions: Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell); Drug: Pembrolizumab Injection [Keytruda]
Sponsor: SMT bio Co., Ltd.
Not yet recruiting

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Posted: April 9th, 2019, 2:00pm GMT

Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic
Interventions: Drug: TC-210 T Cells; Drug: fludarabine; Drug: cyclophosphamide; Biological: anti-PD1
Sponsor: TCR2 Therapeutics
Recruiting

Combination of Radiotherapy With Anti PD-1/PD-L1 Antibodies for Unresectable ICC

Posted: April 2nd, 2019, 2:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma; Radiotherapy; Immunotherapy
Interventions: Combination Product: Radiotherapy+anti-PD-1; Drug: Gemcitabine+cisplatin
Sponsor: Sun Yat-sen University
Not yet recruiting

Permalink for 'The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)'

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Posted: April 1st, 2019, 2:00pm GMT

Conditions: Cancer, All Types; Cancer of Liver; Cancer of Stomach; Cancer of Head and Neck; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Colon; Cancer Skin; Cancer of Cervix; Cancer, Metastatic; Cancer of Larynx; Cancer of Neck; Cancer of Lung; Cancer of Brain and Nervous System; Cancer of Vulva, Disseminated; Cancer of Pancreas; Sarcoma; GIST; Small-cell Lung Cancer; Adenocarcinoma Lung; Cancer of Prostate; Cancer, Advanced; Adrenal Cancer; Testicular Cancer; Uterine Cancer; Bronchoalveolar Cell Lung Cancer; Cancer Unknown Primary; Glioblastoma Multiforme; Oligodendroglioma; Breast Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Cholangiocarcinoma; Squamous Cell Carcinoma; Transitional Cell Carcinoma; Cancer, Other; Cancer, Anal; Melanoma; Cancer, Bile Duct; Cancer, Bladder; Cancer Cords Vocal; Cancers Cell Neuroendocrine; Cancer Differentiated Poorly; Cancer, Anaplastic Thyroid
Intervention:
Sponsors: SpeciCare; Dana-Farber Cancer Institute; Kalispell Regional Medical Center; Georgia Institute of Technology; Ontario Institute for Cancer Research; SEngine Precision Medicine; Helomics
Recruiting

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Posted: March 29th, 2019, 2:00pm GMT

Conditions: Liver Neoplasm Malignant Primary; Cholangiocarcinoma; Combinational Immunotherapy; Biomarker
Intervention: Drug: Lenvatinib plus Pembrolizumab
Sponsor: Peking Union Medical College Hospital
Recruiting

Olaparib and Ceralasertib in Treating Patients With IDH Mutant Cholangiocarcinoma or Solid Tumors

Posted: March 18th, 2019, 2:00pm GMT

Conditions: Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Drug: Ceralasertib; Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Posted: March 13th, 2019, 2:00pm GMT

Conditions: Solid Tumor; Colon Cancer; Cholangiocarcinoma; Bladder Cancer; Ovarian Cancer; Gastric Cancer; Palpable Subcutaneous Malignant Lesions
Interventions: Biological: TRK-950; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Gemcitabine; Drug: Cisplatin; Drug: Carboplatin; Biological: Ramucirumab; Drug: Paclitaxel; Biological: Nivolumab; Biological: Pembrolizumab; Drug: Imiquimod Cream
Sponsor: Toray Industries, Inc
Recruiting

Toripalimab or Placebo as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Posted: March 8th, 2019, 3:00pm GMT

Condition: Epatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Intervention: Biological: TORIPALIMAB INJECTION(JS001 )
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting

Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images

Posted: February 25th, 2019, 3:00pm GMT

Conditions: Gallstone; Cholangitis; Cholangiocarcinoma; Pancreatitis; Pancreatic Ductal Adenocarcinoma
Intervention: Other: ultra-rapid acquisition of bile ducts images
Sponsor: IHU Strasbourg
Recruiting

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Posted: February 21st, 2019, 3:00pm GMT

Conditions: Melanoma; Cervical Carcinoma; Pancreatic Carcinoma; Triple Negative Breast Cancer; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Renal Cell Carcinoma; Non-small Cell Lung Carcinoma; Small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced or Metastatic Solid Tumors; Prostate Carcinoma; MSI-H; Mismatch Repair Deficiency; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Biological: XmAb®22841; Biological: Pembrolizumab (Keytruda®)
Sponsors: Xencor, Inc.; ICON Clinical Research
Recruiting

Permalink for 'M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)'

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Posted: February 7th, 2019, 3:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting

TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers

Posted: February 4th, 2019, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Metastatic Castration Resistant Prostate Cancer; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple-Negative Breast Cancer; Urothelial Carcinoma; Cholangiocarcinoma; GastroEsophageal Cancer; Pancreatic Cancer; Sarcoma
Interventions: Drug: Part 1 TPST-1120; Drug: Part 2a TPST-1120 + nivolumab; Drug: Part 2b TPST-1120 + docetaxel; Drug: Part 2c TPST-1120 + cetuximab; Drug: Part 3 TPST-1120; Drug: Part 4a TPST-1120 + nivolumab; Drug: Part 4b TPST-1120 + docetaxel; Drug: Part 4c TPST-1120 + cetuximab
Sponsor: Tempest Therapeutics
Recruiting

Clinical Trial of Autologous Tcm Immunotherapy in ICC

Posted: January 29th, 2019, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Biological: autologous Tcm cellular immunotherapy
Sponsors: Newish Technology (Beijing) Co., Ltd.; Peking Union Medical College Hospital
Not yet recruiting

A Phase 1 Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Posted: January 29th, 2019, 3:00pm GMT

Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting

Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer

Posted: January 28th, 2019, 3:00pm GMT

Conditions: Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Unresectable Esophageal Carcinoma; Unresectable Pancreatic Carcinoma
Intervention: Dietary Supplement: Zinc
Sponsor: Emory University
Recruiting

Permalink for 'Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers'

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Posted: January 14th, 2019, 3:00pm GMT

Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Recruiting

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Posted: January 11th, 2019, 3:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: Lenvatinib
Sponsor: Sun Yat-sen University
Recruiting

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

Posted: January 11th, 2019, 3:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms
Intervention: Biological: Tumor Infiltrating Lymphocytes (TIL)
Sponsor: Udai Kammula
Recruiting

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Posted: December 20th, 2018, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases
Intervention: Drug: MIV-818
Sponsor: Medivir
Recruiting

Phase 3 Study of BJG398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Posted: December 12th, 2018, 3:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Interventions: Drug: BGJ398; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: QED Therapeutics, Inc.
Recruiting

Trial of IRE in Cholangiocarcinoma

Posted: December 7th, 2018, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Device: IRE Device
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting

Permalink for 'Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers'

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Posted: December 7th, 2018, 3:00pm GMT

Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

Posted: December 5th, 2018, 3:00pm GMT

Condition: Primary Sclerosing Cholangitis (PSC)
Intervention: Device: SpyGlass DS I - II
Sponsor: Boston Scientific Corporation
Recruiting

A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors

Posted: November 8th, 2018, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer
Intervention: Drug: ZSP1241
Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Recruiting

Primary EUS-GBD in Patients With Unresectable Malignant Biliary Obstruction and Cystic Duct Orifice Involvement.

Posted: November 5th, 2018, 3:00pm GMT

Condition: Acute Cholecystitis
Interventions: Procedure: EUS-guided gallbladder drainage; Procedure: Non EUS-guided gallbladder drainage
Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas
Recruiting

Permalink for 'A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma'

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Posted: October 3rd, 2018, 2:00pm GMT

Conditions: Colorectal Cancer; Cholangiocarcinoma
Interventions: Device: Medtronic pump and Codman catheter; Drug: Floxuridine (FUDR); Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Irinotecan (CPT-11); Drug: Fluorouracil; Drug: Anti-EGFR (Panitumumab or Cetuximab)
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting

A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Posted: September 26th, 2018, 2:00pm GMT

Conditions: Cohort 1a and 1b: Glioma; Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations
Interventions: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin
Sponsor: Forma Therapeutics, Inc.
Recruiting

Permalink for 'A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)'

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

Posted: September 3rd, 2018, 2:00pm GMT

Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting

Personal Resilience Empowerment Program Study

Posted: August 23rd, 2018, 2:00pm GMT

Conditions: Lung Cancer; Cholangiocarcinoma; Pancreatic Cancer; Liver Cancer
Intervention: Behavioral: Personal Resilience Empowerment Program including 5 sessions with health coaches
Sponsor: Hackensack Meridian Health
Recruiting

Fluorescence Image Guided Surgery in Cholangiocarcinoma

Posted: August 8th, 2018, 2:00pm GMT

Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Bevacizumab-IRDye800CW; Device: near infrared (NIR) fluorescence imaging
Sponsor: University Medical Center Groningen
Recruiting

Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members

Posted: August 2nd, 2018, 2:00pm GMT

Condition: Gastrointestinal Cancer
Interventions: Other: Surgeon-palliative care team co management; Other: Surgeon team alone management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Recruiting

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Posted: July 27th, 2018, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: mFOLFOXIRI
Sponsor: Khon Kaen University
Recruiting

Prospective Surveillance for Very Early Hepatocellular Carcinoma

Posted: July 17th, 2018, 2:00pm GMT

Condition: Carcinoma, Hepatocellular
Intervention:
Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting

Ph1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors

Posted: July 11th, 2018, 2:00pm GMT

Condition: Solid Tumor
Intervention: Drug: EOC317
Sponsor: EddingPharm Oncology Co., LTD.
Recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Posted: July 9th, 2018, 2:00pm GMT

Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Recruiting

Permalink for 'Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer'

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

Posted: June 20th, 2018, 2:00pm GMT

Conditions: Breast Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Gastric Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Prostate Carcinoma
Interventions: Other: Interview; Other: Survey Administration
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting

EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice

Posted: April 11th, 2018, 2:00pm GMT

Conditions: Pancreatic Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Ampulla of Vater Cancer; Jaundice, Obstructive
Intervention: Diagnostic Test: Endoscopic ultrasound
Sponsors: Clinical Hospital Colentina; Catholic University, Italy
Recruiting

Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program

Posted: March 23rd, 2018, 2:00pm GMT

Conditions: Pancreatic Cancer; Liver Cancer; Bile Duct Cancer; Hepatobiliary Cancer; Surgery
Interventions: Other: Exercise; Other: Nutrition; Behavioral: Relaxation techniques
Sponsors: McGill University Health Center; Dr. Franco Carli
Recruiting

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Posted: March 22nd, 2018, 2:00pm GMT

Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma Non-resectable; Gallbladder Carcinoma Non-Resectable
Interventions: Biological: Durvalumab; Drug: Gemcitabine; Drug: Cisplatin; Biological: Tremelimumab
Sponsors: AIO-Studien-gGmbH; AstraZeneca
Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Posted: March 2nd, 2018, 3:00pm GMT

Conditions: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer
Intervention: Other: Clinical Trial Matching
Sponsor: Massive Bio, Inc.
Recruiting

Fluorescence QRH-882260 Peptide Imaging in the Bile Duct

Posted: February 19th, 2018, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: QRH-882260 Heptapeptide
Sponsors: D. Kim Turgeon, MD; University of Washington
Recruiting

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Posted: February 6th, 2018, 3:00pm GMT

Conditions: Breast Cancer; Colorectal Cancer; Cholangiocellular Carcinoma; Sarcoma; Desmoid Tumour; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Posted: January 24th, 2018, 3:00pm GMT

Conditions: Liver Cancer; Liver Metastases
Intervention: Radiation: SBRT
Sponsor: Centre Oscar Lambret
Recruiting

Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study

Posted: January 23rd, 2018, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma, Intrahepatic; Liver Cirrhosis; Liver Cancer; Liver Neoplasms; Liver Diseases
Interventions: Diagnostic Test: contrast enhanced ultrasound (CEUS); Diagnostic Test: MRI; Diagnostic Test: Histology
Sponsor: University Hospital Erlangen
Recruiting

A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma

Posted: December 19th, 2017, 3:00pm GMT

Conditions: Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Perihilar; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic
Intervention: Drug: ABC294640
Sponsor: RedHill Biopharma Limited
Recruiting

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Posted: November 13th, 2017, 3:00pm GMT

Conditions: Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer
Intervention: Drug: Abemaciclib
Sponsors: Jules Bordet Institute; Eli Lilly and Company
Recruiting

A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Posted: November 6th, 2017, 3:00pm GMT

Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Other Solid Tumors; Diffuse Large B-cell Lymphoma (DLBCL); Mantle Cell Lymphoma; Indolent B-cell Lymphomas; Non-Hodgkin Lymphoma
Interventions: Drug: CDX-1140; Drug: CDX-301
Sponsor: Celldex Therapeutics
Recruiting

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Posted: August 22nd, 2017, 2:00pm GMT

Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting

Permalink for 'A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma'

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Posted: August 15th, 2017, 2:00pm GMT

Conditions: Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer; Cholangiocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: Entinostat; Drug: Nivolumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Bristol-Myers Squibb
Recruiting

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

Posted: July 12th, 2017, 2:00pm GMT

Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Melanoma; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Skin Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Intestinal Neoplasms; Thyroid Cancer; GIST; Malignant Peripheral Nerve Sheath Tumors; Breast Secretory Carcinoma; Uterine Neoplasms; Fibrosarcoma; Infantile Fibrosarcoma; Congenital Mesoblastic Nephroma; Central Nervous System Neoplasms
Intervention: Drug: LOXO-195
Sponsor: Bayer
Recruiting

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

Posted: June 7th, 2017, 2:00pm GMT

Conditions: Autoimmune Liver Disease; Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Intervention:
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting

Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer

Posted: May 24th, 2017, 2:00pm GMT

Condition: Pancreatic Cancer Non-resectable
Intervention: Biological: V3-P
Sponsor: Immunitor LLC
Recruiting

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Posted: May 11th, 2017, 2:00pm GMT

Conditions: Solid Tumor, Adult; Breast Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Ovarian Cancer; Endometrial Cancer; Head and Neck Cancer; Cholangiocarcinoma
Intervention: Drug: CX-2009
Sponsor: CytomX Therapeutics
Recruiting

Permalink for 'An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies'

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Posted: May 9th, 2017, 2:00pm GMT

Conditions: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Solid Tumors
Intervention: Drug: INCB062079
Sponsor: Incyte Corporation
Recruiting

Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer

Posted: May 3rd, 2017, 2:00pm GMT

Conditions: Colon Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Pancreatic Carcinoma
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Other: Laboratory Procedure
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting

Permalink for 'Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)'

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Posted: April 13th, 2017, 2:00pm GMT

Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting

Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

Posted: April 7th, 2017, 2:00pm GMT

Condition: Cholangitis
Intervention: Procedure: Injection of 37℃ contrast agent
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting

Permalink for 'A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors'

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Posted: March 7th, 2017, 3:00pm GMT

Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Posted: February 20th, 2017, 3:00pm GMT

Conditions: Melanoma; Head and Neck Cancer; Lymphoma; Breast Cancer; Pancreatic Cancer; Liver Cancer; Colon Cancer; Lung Cancer; Glioblastoma; Bile Duct Cancer; Ovarian Cancer; Sarcoma; Squamous Cell Carcinoma
Interventions: Drug: INT230-6; Biological: anti-PD-1 antibody; Biological: anti-CTLA-4 antibody
Sponsor: Intensity Therapeutics, Inc.
Recruiting

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

Posted: February 7th, 2017, 3:00pm GMT

Conditions: Adenocarcinoma Metastatic; Biliary Tract Cancer; Adenocarcinoma of the Biliary Tract; Adenocarinoma Locally Advanced; Non-Resectable Hepatocellular Carcinoma; Intrahepatic Bile Duct Carcinoma; Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Drug: Arm Cisplatin + Gemcitabine (Arm B)
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire, Baxalta); Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH
Recruiting

Permalink for 'Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies'

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Posted: February 6th, 2017, 3:00pm GMT

Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire)
Recruiting

Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Posted: February 3rd, 2017, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Biological: Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
Sponsor: Immunitor LLC
Recruiting

Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers

Posted: December 26th, 2016, 3:00pm GMT

Conditions: Cholangiocarcinoma; Tumor; Klatskin Tumor
Intervention: Drug: Temoporfin
Sponsor: Chinese University of Hong Kong
Recruiting

A Study of ABBV-181 in Participants With Advanced Solid Tumors

Posted: December 22nd, 2016, 3:00pm GMT

Condition: Advanced Solid Tumors
Interventions: Drug: Venetoclax; Drug: Rovalpituzumab Tesirine; Drug: ABBV-181
Sponsor: AbbVie
Recruiting

Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

Trial - Cholangiocarcinoma (100 unread)

Posted: November 8th, 2019, 3:00pm GMT

Posted: November 5th, 2019, 3:00pm GMT

Posted: November 4th, 2019, 3:00pm GMT

Posted: October 30th, 2019, 2:00pm GMT

Posted: October 24th, 2019, 2:00pm GMT

Posted: October 21st, 2019, 2:00pm GMT

Posted: September 26th, 2019, 2:00pm GMT

Posted: September 23rd, 2019, 2:00pm GMT

Posted: September 18th, 2019, 2:00pm GMT

Posted: September 12th, 2019, 2:00pm GMT

Posted: September 12th, 2019, 2:00pm GMT

Posted: September 5th, 2019, 2:00pm GMT

Posted: September 4th, 2019, 2:00pm GMT

Posted: September 4th, 2019, 2:00pm GMT

Posted: September 2nd, 2019, 2:00pm GMT

Posted: August 28th, 2019, 2:00pm GMT

Posted: August 26th, 2019, 2:00pm GMT

Posted: August 23rd, 2019, 2:00pm GMT

Posted: August 20th, 2019, 2:00pm GMT

Posted: August 19th, 2019, 2:00pm GMT

Posted: August 16th, 2019, 2:00pm GMT

Posted: August 2nd, 2019, 2:00pm GMT

Posted: July 30th, 2019, 2:00pm GMT

Posted: July 26th, 2019, 2:00pm GMT

Posted: July 22nd, 2019, 2:00pm GMT

Posted: July 10th, 2019, 2:00pm GMT

Posted: July 1st, 2019, 2:00pm GMT

Posted: June 27th, 2019, 2:00pm GMT

Posted: June 24th, 2019, 2:00pm GMT

Posted: June 19th, 2019, 2:00pm GMT

Posted: June 19th, 2019, 2:00pm GMT

Posted: June 11th, 2019, 2:00pm GMT

Posted: May 15th, 2019, 2:00pm GMT

Posted: May 9th, 2019, 2:00pm GMT

Posted: May 8th, 2019, 2:00pm GMT

Posted: May 7th, 2019, 2:00pm GMT

Posted: May 6th, 2019, 2:00pm GMT

Posted: April 9th, 2019, 2:00pm GMT

Posted: April 2nd, 2019, 2:00pm GMT

Posted: April 1st, 2019, 2:00pm GMT

Posted: March 29th, 2019, 2:00pm GMT

Posted: March 18th, 2019, 2:00pm GMT

Posted: March 13th, 2019, 2:00pm GMT

Posted: March 8th, 2019, 3:00pm GMT

Posted: February 25th, 2019, 3:00pm GMT

Posted: February 21st, 2019, 3:00pm GMT

Posted: February 7th, 2019, 3:00pm GMT

Posted: February 4th, 2019, 3:00pm GMT

Posted: January 29th, 2019, 3:00pm GMT

Posted: January 29th, 2019, 3:00pm GMT

Posted: January 28th, 2019, 3:00pm GMT

Posted: January 14th, 2019, 3:00pm GMT

Posted: January 11th, 2019, 3:00pm GMT

Posted: January 11th, 2019, 3:00pm GMT

Posted: December 20th, 2018, 3:00pm GMT

Posted: December 12th, 2018, 3:00pm GMT

Posted: December 7th, 2018, 3:00pm GMT

Posted: December 7th, 2018, 3:00pm GMT

Posted: December 5th, 2018, 3:00pm GMT

Posted: November 8th, 2018, 3:00pm GMT

Posted: November 5th, 2018, 3:00pm GMT

Posted: October 3rd, 2018, 2:00pm GMT

Posted: September 26th, 2018, 2:00pm GMT

Posted: September 3rd, 2018, 2:00pm GMT

Posted: August 23rd, 2018, 2:00pm GMT

Posted: August 8th, 2018, 2:00pm GMT

Posted: August 2nd, 2018, 2:00pm GMT

Posted: July 27th, 2018, 2:00pm GMT

Posted: July 17th, 2018, 2:00pm GMT

Posted: July 11th, 2018, 2:00pm GMT

Posted: July 9th, 2018, 2:00pm GMT

Posted: June 20th, 2018, 2:00pm GMT

Posted: April 11th, 2018, 2:00pm GMT